Treatment of walking impairment in multiple sclerosis with dalfampridine

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 2, 2011, Pages 99-109

  Blight, Andrew R ^a  

^a ACORDA THERAPEUTICS INC   (United States)

Author keywords

4 aminopyridine; dalfampridine; fampridine; multiple sclerosis; potassium channel blockade; walking speed

Indexed keywords

4 AMINOPYRIDINE; DALFAMPRIDINE; PLACEBO; TETRYLAMMONIUM CHLORIDE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACTION POTENTIAL; ANKLE FRACTURE; ANXIETY; ASTHENIA; ATAXIA; BALANCE DISORDER; CENTRAL NERVOUS SYSTEM; COMPLEX PARTIAL SEIZURE; CONFUSION; CONTROLLED RELEASE FORMULATION; CONVULSION; DEMYELINATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE TEST; EXPANDED DISABILITY STATUS SCALE; GAIT; HUMAN; HYPOTENSION; INSOMNIA; LIMB WEAKNESS; LIVER DYSFUNCTION; MOTOR COORDINATION; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; NAUSEA; NERVE CONDUCTION; OPTIC NEURITIS; PAIN; PARESTHESIA; PATELLA FRACTURE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SPASTIC PARAPLEGIA; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; TEMPERATURE SENSITIVITY; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WALKING DIFFICULTY; WALKING SPEED;

EID: 79956050410     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611403960     Document Type: Review

References (68)

1. Albrecht H. Wötzel C. Erasmus L.P. Kleinpeter M. König N. Pöllmann W. (2001) Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): Average walking speed is a more constant parameter. Mult Scler 7: 105–109.
2. Amato M.P. Fratiglione L. Groppi C. Siracuse G. Amaducci L. (1989) Interrater reliability in assessing functional systems and disability on the Kurtzke Scale in multiple sclerosis. Arch Neurol 45: 746–748.
3. Ball A.P. Hopkinson R.B. Farrell I.D. Hutchison J.G. Paul R. Watson R.D. et al (1979) Human botulism caused by Clostridium botulinum type E: The Birmingham outbreak. QJM 48: 473–491.
4. Bever C.T. Jr (2005) Clinical pharmacology of abnormal potassium channel organization in demyelinated axons. In: Ed. Waxman S.G. (ed.). Multiple Sclerosis as a Neuronal Disease, Elsevier Academic Press: Amsterdam.
5. Bever C.T. Jr (2009) 10 questions about 4-aminopyridine and the treatment of multiple sclerosis. Neurologist 15: 161–162.
6. Bever C.T. Jr Judge S.I. (2009) Sustained-release fampridine for multiple sclerosis. Expert Opin Investig Drugs 18: 1013–1024.
7. Bever C.T. Jr Young D. Anderson P.A. Krumholz A. Conway K. Leslie J. et al (1994) The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44: 1054–1059.
8. Blight A.R. (1989) Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 22: 47–52.
9. Bostock H. Sears T.A. Sherratt R.M. (1981) The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 313: 301–315.
10. Bostock H. Sherratt R.M. Sears T.A. (1978) Overcoming conduction failure in demyelinated nerve fibres by prolonging action potential. Nature 274: 385–387.
11. Canadian Cooperative Multiple Sclerosis Study Group (CCMSSG). (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337: 441–446.
12. Cohen J.T. (2010) Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res 10: 595–603.
13. Compston A. Coles A. (2008) Multiple sclerosis. Lancet 372: 1502–1517.
14. Davis F.A. Stefoski D. Rush J. (1990) Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 27: 186–192.
15. Dobkin B.H. (2006) Short-distance walking speed and timed walking distance: Redundant measures for clinical trials? Neurology 66: 584–586.
16. Einarsson U. Gottberg K. von Koch L. Fredrikson S. Ytterberg C. Jin Y.P. et al (2006) Cognitive and motor function in people with multiple sclerosis in Stockholm County. Mult Scler 12: 340–353.
17. Fahey M.C. Corben L.A. Collins V. Churchyard A.J. Delatycki M.B. (2007) The 25-foot walk velocity accurately measures real world ambulation in Friedreich ataxia. Neurology 68: 705–706.
18. Fischer J.S. Rudick R.A. Cutter G.R. Reingold S.C. (1999) The Multiple Sclerosis Functional Composite Measure (MSFC): An integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 5: 244–250.
19. Francis D.A. Bain P. Swan A.V. Hughes A.C. (1991) An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 48: 291–301.
20. Frohman E.M. (2003) Multiple sclerosis. Med Clin North Am 87: 867–897.
21. Goodman A.D. Brown T.R. Cohen J.A. Krupp L.B. Schapiro R. Schwid S.R. et al Fampridine MS-F202 Study Group. (2008) Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 71: 1134–1141.
22. Goodman A.D. Brown T.R. Edwards K.R. Krupp L.B. Schapiro R.T. Cohen R. et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68: 494–502.
23. Goodman A.D. Brown T.R. Krupp L.B. Schapiro R.T. Schwid S.R. Cohen R. et al Fampridine MS-F203 Investigators. (2009) Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet 373: 732–738.
24. Goodman A.D. Cohen J.A. Cross A. Vollmer T. Rizzo M. Cohen R. et al (2007) Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13: 357–368.
25. Hobart J.C. Freeman J. Thompson A. (2000) Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain 123: 1027–1040.
26. Hobart J.C. Riazi A. Lamping D.L. Fitzpatrick R. Thompson A.J. (2003) Measuring the impact of MS on walking ability: The 12-item MS Walking Scale (MSWS-12). Neurology 60: 31–36.
27. Hoogervorst E.L.J. Kalkers N.F. Cutter G.R. Uitdehaag B.M.J. Polman C.H. (2004) The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 10: 55–60.
28. Jensen J.M. Shi R. (2003) Effects of 4-aminopyridine on stretched mammalian spinal cord: The role of potassium channels in axonal conduction. J Neurophysiol 90: 2334–2340.
29. Jones R.F. Heron J.R. Foster D.H. Snelgar R.S. Mason R.J. (1983) Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 60: 353–362.
30. Kaufman M. Moyer D. Norton J. (2000) The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite. Mult Scler 6: 286–290.
31. Kocsis J.D. Bowe C.M. Waxman S.G. (1986) Different effects of 4-aminopyridine on sensory and motor fibers: Pathogenesis of paresthesias. Neurology 36: 117–120.
32. Kragt J.J. van der Linden F.A.H. Nielsen J.M. Uitdehaag B.M.J. Polman C.H. (2006) Clinical impact of 20% worsening on Timed 25-Foot Walk and 9-Hole Peg Test in multiple sclerosis. Mult Scler 12: 594–598.
33. Kurtzke J.F. (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444–1452.
34. Lundh H. (1978) Effects of 4-aminopyridine on neuromuscular transmission. Brain Res 153: 307–318.
35. Lundh H. Nilsson O. Rosén I. (1979) Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry 42: 171–175.
36. McDonald W.I. (1974) Pathophysiology in multiple sclerosis. Brain 97: 179–196.
37. McGuigan C. Hutchinson M. (2004) Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12). Neurology 62: 2103–2105.
38. Meves H. Pichon Y. (1977) The effect of internal and external 4-aminopyridine on the potassium currents in intracellularly perfused squid giant axons. J Physiol 268: 511–532.
39. Motl R.W. Snook E.M. (2008) Confirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12. J Neurol Sci 268: 69–73.
40. Murray N.M. Newsom-Davis J. (1981) Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 31: 265–271.
41. National Multiple Sclerosis Society (NMSS). About MS: Who Gets MS? [http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx; accessed 27 July 2010].
42. Noseworthy J.H. Vandervoort M.K. Wong C.J. Ebers G.C. Canadian Cooperative MS Study Group. (1990) Interrater variability with Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis trial. Neurology 40: 971–975.
43. Pearson O.R. Busse M.E. van Deursen R.W. Wiles C.M. (2004) Quantification of walking mobility in neurological disorders. QJM 97: 463–475.
44. Pelhate M. Mony L. Hue B. Chanelet J. (1975) Modification of potassium current by 4-aminopyridine. Case of the isolated giant axon of the cockroach (Periplanata americana). CR Seances Soc Biol Fil 169: 1436–1441.
45. Polman C.H. Bertelsmann F.W. van Loenen A.C. Koetsier J.C. (1994) 4-aminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 51: 292–296.
46. Polman C.H. Rudick R.A. (2010) The multiple sclerosis functional composite: A clinically meaningful measure of disability. Neurology 74: S8–S15.
47. Rasband M.N. (2005) Potassium channel organization of myelinated and demyelinated axons. In: Ed. Waxman S.G. (ed.). Multiple Sclerosis as a Neuronal Disease, Elsevier Academic Press: Amsterdam.
48. Rasminsky M. (1973) The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol 28: 287–292.
49. Schauf C.L. Davis S.A. (1974) Impulse conduction in multiple sclerosis: A theoretical basis for modification by temperature and pharmacological agents. J Neurol Neurosurg Psychiatry 37: 152–161.
50. Schmid A. Duncan P.W. Studenski S. Lai S.M. Richards L. Perera S. et al (2007) Improvements in speed-based gait classifications are meaningful. Stroke 38: 2096–2100.
51. Schwid S.R. Goodman A.D. McDermott M.P. Bever C.F. Cook S.D. (2002) Quantitative functional measures in MS: What is a reliable change? Neurology 58: 1294–1296.
52. Schwid S.R. Petrie M.D. McDermott M.P. Tierney D.S. Mason D.H. Goodman A.D. (1997) Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 48: 817–821.
53. Sherratt R.M. Bostock H. Sears T.A. (1980) Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibers. Nature 283: 570–572.
54. Sharrack B. Hughes R.A.C. Soudain S. Dunn G. (1999) The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 122: 141–159.
55. Shi R. Blight A.R. (1997) Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 77: 553–562.
56. Shi R. Kelly T.M. Blight A.R. (1997) Conduction block in acute and chronic spinal cord injury: Different dose-response characteristics for reversal by 4-aminopyridine. Exp Neurol 148: 495–501.
57. Smith K.J. McDonald W.I. (1999) The pathophysiology of multiple sclerosis: The mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 354: 1649–1673.
58. Snook E.M. Motl R.W. Gliottoni R.C. (2009) The effect of walking mobility on the measurement of physical activity using accelerometry in multiple sclerosis. Clin Rehabil 23: 248–258.
59. Sosnoff J.J. Goldman M.D. Motl R.W. (2010) Real-life walking impairment in multiple sclerosis: Preliminary comparison of four methods for processing accelerometry data. Mult Scler 16: 868–877.
60. Stefoski D. Davis F.A. Faut M. Schauf C.L. (1987) 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 21: 71–77.
61. Stefoski D. Davis F.A. Fitzsimmons W.E. Luskin S.S. Rush J. Parkhurst G.W. (1991) 4-aminopyridine in multiple sclerosis: Prolonged administration. Neurology 41: 1344–1348.
62. Targ E.F. Kocsis J.D. (1985) 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 328: 358–361.
63. van de Port I.G. Kwakkei G. Lindeman E. (2008) Community ambulation in patients with chronic stroke: How is it related to gait speed? J Rehabil Med 40: 23–27.
64. van Diemen H.A. Polman C.H. Koetsler J.C. van Loenen A.C. Nauta J.J. Bertelsmann F.W. (1993) 4-aminopyridine in patients with multiple sclerosis: Dosage and serum level related to efficacy and safety. Clin Neuropharmacol 16: 195–204.
65. van Diemen H.A. Polman C.H. van Dongen T.M. van Loenen A.C. Nauta J.J. Taphoorn M.J. et al (1992) The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 32: 123–130.
66. Waxman S.G. (1982) Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 306: 1529–1533.
67. Yeh J.Z. Oxford G.S. Wu C.H. Narahashi T. (1976) Interactions of aminopyridines with potassium channels of squid axon membranes. Biophys J 16: 77–81.
68. Zwibel H. (2009) Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 261: 1043–1057.